Clinical Trial Update: The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating switching between Humira and BI 695501 in plaque psoriasis completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• BI 695501
• Humira (adalimumab)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2021-07-02